PDE4A, phosphodiesterase 4A, 5141

N. diseases: 168; N. variants: 3
Disease: Lung diseases ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.040 Biomarker group BEFREE CHF6001 is a new and potent PDE4 inhibitor for the treatment of human lung diseases, designed for topical administration by inhalation. 29307855 2018
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.040 Biomarker group BEFREE Cilomilast is a phosphodiesterase 4 (PDE4) inhibitor for treating inflammatory lung diseases. 29602314 2018
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.040 Biomarker group BEFREE This review focuses on clinical data on PDE4 inhibitors and its future roles in asthma, COPD, bronchiectasis, ACOS and other chronic non-pulmonary diseases. 28523172 2017
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.040 Biomarker group BEFREE Inhibition of PDE4 inhibition (rather than PDE3) may diminish proliferation of human lung fibroblasts and therefore could be useful in the therapy of pathological remodeling in lung diseases. 20082309 2010